Compare · DHR vs MLAB
DHR vs MLAB
Side-by-side comparison of Danaher Corporation (DHR) and Mesa Laboratories Inc. (MLAB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DHR and MLAB operate in Industrial Machinery/Components (Industrials), so they compete in similar markets.
- DHR is the larger of the two at $151.82B, about 213.0x MLAB ($712.6M).
- DHR has been more active in the news (19 items in the past 4 weeks vs 13 for MLAB).
- DHR has more recent analyst coverage (25 ratings vs 3 for MLAB).
- Company
- Danaher Corporation
- Mesa Laboratories Inc.
- Price
- $215.90+0.34%
- $128.13+3.12%
- Market cap
- $151.82B
- $712.6M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 19
- 13
- Recent ratings
- 25
- 3
Danaher Corporation
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology and molecular diagnostics products. This segment offers analytical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.
Mesa Laboratories Inc.
Mesa Laboratories, Inc. designs, manufactures, and markets quality control instruments and disposable products in the United States, Europe, Asia, North America, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. The company's Instruments segment designs, manufactures, and markets quality control hardware and disposable products used in the healthcare, pharmaceutical, food and beverage, medical device, industrial hygiene, and environmental air sampling industries. This segment's products include dialysate meters and calibration solutions, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. The company's Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The company's Continuous Monitoring segment designs, develops, and markets systems, which are used to monitor various environmental parameters, such as temperature, humidity, and differential pressure to ensure that critical storage and processing conditions are maintained in hospitals, pharmaceutical and medical device manufacturers, blood banks, pharmacies, and laboratory environments. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.
Latest DHR
- President & CEO Blair Rainer sold $12,736,095 worth of shares (58,255 units at $218.63) (SEC Form 4)
- Executive Vice President Riley Christopher Paul was granted 41,072 shares, increasing direct ownership by 201% to 61,472 units (SEC Form 4)
- SEC Form 4 filed by EVP & Chief Financial Officer Gugino Matthew E
- SEC Form 4 filed by SVP-Chief Legal Officer Leiken Jonathan
- SVP, Chief Science Officer Gutierrez-Ramos Jose-Carlos was granted 13,477 shares, increasing direct ownership by 71% to 32,495 units (SEC Form 4)
- SEC Form 4 filed by Executive Vice President Sawyer Montgomery Julie A
- SEC Form 4 filed by VP, Chief Accounting Officer Bouda Christopher
- Executive Vice President Milosevich Gregory M was granted 15,402 shares, increasing direct ownership by 170% to 24,467 units (SEC Form 4)
- Chairman of Exec. Committee Rales Mitchell P was granted 500,000 shares, increasing direct ownership by 939% to 553,228 units (SEC Form 4)
- Chairman Rales Steven M was granted 500,000 shares, increasing direct ownership by 16% to 3,605,808 units (SEC Form 4)
Latest MLAB
- Director Capone Mark Christopher converted options into 2,784 shares, increasing direct ownership by 81% to 6,213 units (SEC Form 4)
- Director Alltoft Jennifer Sadie converted options into 2,784 shares, increasing direct ownership by 57% to 7,662 units (SEC Form 4)
- Director Ladiwala Shiraz Shabanali converted options into 3,810 shares, increasing direct ownership by 45% to 12,333 units (SEC Form 4)
- Director Hall Shannon converted options into 2,784 shares, increasing direct ownership by 66% to 6,973 units (SEC Form 4)
- Director Tripeny R Tony converted options into 2,784 shares, increasing direct ownership by 44% to 9,082 units (SEC Form 4)
- Director Sullivan John James converted options into 2,784 shares, increasing direct ownership by 16% to 20,618 units (SEC Form 4)
- Director Sullivan John James sold $800,090 worth of shares (7,093 units at $112.80), decreasing direct ownership by 28% to 17,834 units (SEC Form 4)
- President and CEO Kadia Siddhartha bought $800,090 worth of shares (7,093 units at $112.80) (SEC Form 4)
- Director Tripeny R Tony bought $102,321 worth of shares (900 units at $113.69), increasing direct ownership by 17% to 6,298 units (SEC Form 4)
- SEC Form 10-Q filed by Mesa Laboratories Inc.